Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + interferon alpha
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous, Intramuscular
01
Overview
Toripalimab + interferon alpha is an investigational combination immunotherapy being evaluated for the treatment of head and neck squamous cell carcinoma (HNSCC). Toripalimab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with ligands PD-L1 and PD-L2 to restore T-cell mediated anti-tumor activity. Interferon alpha is a cytokine that enhances the immune response by promoting the maturation of dendritic cells, increasing MHC class I expression, and potentially overcoming resistance to PD-1 blockade. This combination is being studied, notably by the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, to improve response rates in patients with recurrent or metastatic HNSCC who may have limited options with standard therapies.
- Brand names
- Tuoyi
- Other names
- Toripalimab plus IFN-alphaToripalimab combined with Interferon-alpha
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on toripalimab + interferon alpha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + interferon alpha.